Why Type 2 Diabetes Is More Than Blood Sugar
Type 2 diabetes mellitus, often called T2DM, is a chronic metabolic condition closely linked to insulin resistance. This means the body has trouble using insulin properly, which can lead to elevated blood glucose levels over time.
While blood sugar is a major part of diabetes management, T2DM is more than a glucose issue alone. It can also involve chronic low-grade inflammation, metabolic stress, changes in liver and kidney function, and reduced insulin sensitivity. Because of this, researchers are continuing to explore approaches that may support the broader metabolic environment involved in diabetes.
One area of growing interest is the use of human umbilical cord-derived mesenchymal stem cells, also known as UC-MSCs.
Why Researchers Are Studying UC-MSCs
Mesenchymal stem cells, or MSCs, are studied in regenerative medicine because they release signaling molecules that may influence inflammation, immune activity, tissue repair, and cell communication.
Umbilical cord-derived MSCs are especially interesting because umbilical cord tissue is considered a young and active source of MSCs. These cells are being studied for their potential to help support a healthier inflammatory and metabolic environment.
For type 2 diabetes, researchers are interested in whether UC-MSCs may help support:
- Improved insulin sensitivity
- Better glycemic control
- Reduced systemic inflammation
- Healthier metabolic function
- Supportive effects on liver and kidney-related markers
Rather than focusing only on lowering blood sugar, this area of research looks at how regenerative cell signaling may influence several diabetes-related pathways at the same time.
Inside the Registry Study
This 2025 retrospective registry study reviewed clinical data from patients with type 2 diabetes who received intravenous allogeneic UC-MSC infusions.
The study included data from:
- 218 patients who completed 6-month follow-up
- 83 patients who completed 12-month follow-up
Patients received 50–100 × 10⁶ allogeneic UC-MSCs through intravenous infusion. Researchers then reviewed blood and urine results at baseline and follow-up.
The study evaluated several health markers, including:
- HbA1c and fasting blood sugar
- Insulin levels and HOMA-IR, a marker of insulin resistance
- Lipid profile
- Liver function markers
- Kidney function markers
- Hormonal markers
- Inflammatory markers such as hs-CRP
This broad approach allowed researchers to look beyond glucose alone and evaluate how UC-MSC infusion may relate to overall metabolic and inflammatory health.
What Researchers Observed
The study reported encouraging findings over the 6- and 12-month follow-up periods.
One of the key findings was a significant reduction in HbA1c, a common marker used to understand average blood sugar levels over time. HbA1c levels were significantly reduced at both 6 months and 12 months after UC-MSC infusion.
The study also reported improvements in insulin-related markers. Insulin levels and HOMA-IR were significantly reduced within 6 months, suggesting improved insulin resistance. A similar favorable trend was also observed at 12 months.
Researchers also found positive changes in several other areas:
- Liver markers: ALT and GGT levels decreased, suggesting improved liver-related inflammatory markers.
- Inflammation: In patients with higher inflammation, hs-CRP levels decreased, with a significant reduction seen at 12 months.
- Kidney markers: In patients with stage 2 chronic kidney disease, eGFR and creatinine improved at follow-up.
- Safety: The study reported satisfactory outcomes without adverse effects.
These findings suggest that UC-MSC infusion may be associated with improvements in several areas connected to type 2 diabetes, including glycemic control, insulin resistance, inflammation, liver profile, and kidney-related markers.
How UC-MSCs May Support Metabolic Health
Type 2 diabetes is often connected with inflammation and metabolic stress. When inflammation remains elevated, it may contribute to insulin resistance and make it harder for the body to regulate glucose effectively.
UC-MSCs may support metabolic health through paracrine signaling, meaning they release helpful molecules that communicate with other cells. These signals may help regulate immune activity, calm excessive inflammation, and support healthier tissue function.
In diabetes research, this is important because several systems are involved at once. Blood sugar regulation, insulin sensitivity, inflammation, liver function, kidney health, and vascular health can all be connected.
The findings from this study suggest that UC-MSCs may influence more than one pathway. By supporting inflammation balance and metabolic regulation, UC-MSCs may help create a more favorable internal environment for patients with type 2 diabetes.
Why These Findings Matter
This study is meaningful because it looks at type 2 diabetes from a broader regenerative medicine perspective. Instead of only measuring blood sugar, the researchers also evaluated insulin resistance, inflammation, liver markers, kidney markers, and hormonal changes.
That broader view is important because T2DM affects the body in multiple ways. A therapy that may support several metabolic and inflammatory pathways could be valuable for future research.
The study also adds to growing interest in UC-MSCs as a potential tool for conditions involving chronic inflammation and metabolic dysfunction. While more controlled research is needed, the results provide a useful foundation for future clinical trials.
Looking Ahead
The findings from this registry study are encouraging and point toward the need for larger, well-designed randomized controlled trials. Future studies can help confirm the results, clarify ideal dosing, identify which patients may benefit most, and better understand how long these effects may last.
As regenerative medicine research continues to evolve, UC-MSCs may become an important area of study for metabolic conditions like type 2 diabetes. Their ability to influence inflammation, immune balance, and repair-related signaling makes them a promising focus for future investigation.
Takeaway
This retrospective registry study suggests that intravenous umbilical cord-derived MSC infusion may be associated with improvements in several important markers related to type 2 diabetes. Patients showed reductions in HbA1c, insulin resistance markers, liver-related inflammatory markers, and systemic inflammation, along with favorable kidney-related changes in certain patients.
While additional controlled studies are needed, this research highlights the potential of UC-MSCs as a regenerative approach aimed at supporting metabolic health, inflammation balance, and healthier cellular communication in type 2 diabetes.
Source
Chin SP, Kee LT, Mohd MA, Then KY. Umbilical Cord-Derived Mesenchymal Stem Cells Infusion in Type 2 Diabetes Mellitus Patients: A Retrospective Cytopeutics’ Registry Study. Diabetes, Metabolic Syndrome and Obesity. 2025 May 19;18:1643–1659. doi: 10.2147/DMSO.S507801. PMID: 40416928; PMCID: PMC12102742. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12102742/
Related Treatment Pages